Skip to main content

ORIGINAL RESEARCH article

Front. Psychiatry
Sec. Schizophrenia
Volume 15 - 2024 | doi: 10.3389/fpsyt.2024.1472671
This article is part of the Research Topic Violence and Mental Health. Focus on Schizophrenia Spectrum and Psychotic Disorders View all articles

Neurofeedback Technique for Treating Male Schizophrenia Patients with Impulsive Behavior: A Randomized Controlled Study

Provisionally accepted
Zhenkuo Li Zhenkuo Li 1,2Hao Ren Hao Ren 3*Yinghan Tian Yinghan Tian 2Jiqian Zhou Jiqian Zhou 1*Wenhao Chen Wenhao Chen 1*Guohua OuYang Guohua OuYang 1*Zhaolai Chen Zhaolai Chen 1*Wei Yi Wei Yi 1*Hongli Song Hongli Song 1*Peng Xie Peng Xie 1*Xinchun Wang Xinchun Wang 1*Xi Chen Xi Chen 1*Qinglin Xiao Qinglin Xiao 1*Huanzhong Liu Huanzhong Liu 2*
  • 1 Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
  • 2 Department of Psychiatry, Chaohu Hospital of Anhui Medical University, Hefei, China
  • 3 Department of Psychiatry, Chongqing Changshou District, Mental Health Center, Chongqing 401231, China, Chongqing, China

The final, formatted version of the article will be published soon.

    Background: Schizophrenia is one of the most severe mental disorders, frequently associated with aggression and violence, particularly in male patients. The underlying mechanisms of violent behavior in these patients remain unclear, limiting effective treatment options and highlighting the need for further research into interventions for impulsive behaviors. This study aims to evaluate the clinical efficacy of neurofeedback treatment in hospitalized male schizophrenia patients exhibiting impulsive behaviors.The study was designed as a single-center, randomized, single-blind, shamcontrolled parallel trial. Eighty patients were randomly assigned to either a study group or a control group. The control group received risperidone and sham neurofeedback, while the study group received risperidone and active neurofeedback therapy. Both groups underwent training five times per week, with each session lasting 20 minutes, over a six-week period. Clinical symptoms were assessed at baseline, three weeks and six weeks using the Positive and Negative Syndrome Scale (PANSS), the Modified Overt Aggression Scale (MOAS), and the Rating Scale for Extrapyramidal Side Effects (RSESE). Statistical analyses were conducted to compare the therapeutic effects between the two groups at the study's conclusion.Results: Initial comparisons showed no significant differences in baseline data, except for the number of prior hospitalizations (P<0.018). By the end of the study, the study group demonstrate significant improvements in MOAS and PANSS scores (including 删除了: among

    Keywords: Clinical trial registration: chictr.org.cn，identifier ChiCTR2200063407 Keywords：Neurofeedback Therapy, male, Schizophrenia, agitation, impulsiveness, PANSS-Excited Component

    Received: 29 Jul 2024; Accepted: 18 Sep 2024.

    Copyright: © 2024 Li, Ren, Tian, Zhou, Chen, OuYang, Chen, Yi, Song, Xie, Wang, Chen, Xiao and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hao Ren, Department of Psychiatry, Chongqing Changshou District, Mental Health Center, Chongqing 401231, China, Chongqing, China
    Jiqian Zhou, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Wenhao Chen, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Guohua OuYang, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Zhaolai Chen, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Wei Yi, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Hongli Song, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Peng Xie, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Xinchun Wang, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Xi Chen, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Qinglin Xiao, Department of Psychiatry, The Fifth People’s Hospital of Xiangtan City, Xiangtan 411100, China, Xiangtan, China
    Huanzhong Liu, Department of Psychiatry, Chaohu Hospital of Anhui Medical University, Hefei, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.